Angiotensin II receptor blocker/ja: Difference between revisions
Angiotensin II receptor blocker/ja
Tags: Mobile edit Mobile web edit |
Created page with "{{clear}}" Tags: Mobile edit Mobile web edit |
||
| Line 336: | Line 336: | ||
</div> | </div> | ||
{{clear}} | {{clear}} | ||
== 外部リンク == | |||
* {{MeshName|Angiotensin II Type 1 Receptor Blockers}} | * {{MeshName|Angiotensin II Type 1 Receptor Blockers}} | ||
* {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }} | * {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }} | ||
{{Major drug groups/ja}} | {{Major drug groups/ja}} | ||